The infectious disease drug developer has applied to float in Hong Kong, which will enable the WuXi AppTec-backed 6 Dimensions Capital to exit.
Brii Biosciences, a China-based chronic disease therapy developer backed by pharmaceutical group WuXi AppTec, has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange. The offering’s lead underwriters are Morgan Stanley Asia and UBS Hong Kong. Although its size and timeline are not yet disclosed, Bloomberg reported in August 2020 the…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.